A new triple receptor drug cut body weight by nearly 20% in 24 weeks

Key Findings

Sleeve gastrectomy still outpaces tirzepatide — especially in minority patients ⚖️

• In a propensity-matched cohort of predominantly minority patients with severe obesity, sleeve gastrectomy produced 30% total weight loss at 12 months versus 12% with tirzepatide.
• BMI dropped about 12 points with surgery versus 7 with the drug. The authors frame tirzepatide as a meaningful non-invasive option, not a replacement, and call for individualized decisions based on goals and cost.

Oral semaglutide for obesity spread fast after approval 📈

• A JAMA Network Open cohort study tracked early prescribing of oral semaglutide among U.S. adults eligible for obesity medications after its approval — and found rapid uptake diffusion across the health system.
• The speed of adoption raises practical questions about who is getting it, whether prescribing patterns mirror those of injectable versions, and whether the equity gaps documented for older agents are repeating themselves.

Only one-third of non-diabetic patients stay on GLP-1 drugs at 12 months 📉

• A lifecycle review of incretin therapies found real-world persistence at roughly one-third at 12 months in people using these drugs for obesity without diabetes — and cost, not side effects, is the dominant reason people stop.
• Weight and cardiometabolic gains reverse toward baseline within months of stopping, and cyclical use — stopping and restarting — has become a common real-world pattern.

Semaglutide improves heart function independent of weight loss — in animals 🐀

• In two preclinical heart failure models — an obese rat and a metabolic-syndrome pig — weight-neutral semaglutide improved coronary blood vessel function, reduced fibrosis, and increased microvascular density in heart tissue.
• The drug also shifted the plasma lipid profile, cutting ceramides and diacylglycerols. These are animal results, so human translation is not established, but the weight-independent mechanism is the signal worth watching.

Safiglipron — a pill GLP-1 drug — beats a standard diabetes drug in a phase 3 trial 💊

• In an 810-person trial in China, safiglipron at 90 mg outperformed dapagliflozin on blood sugar control at 32 weeks, with 48.6% of patients reaching a tight HbA1c target versus 16.1% on dapagliflozin.
• Safiglipron requires no fasting or dietary restrictions for dosing — a practical edge over injectable and some oral GLP-1 formats. Gastrointestinal side effects were more frequent but mostly mild.

GLP-1 drugs are linked to lower Alzheimer's risk — genetics points to the brain, not just metabolism 🧠

• A Mendelian randomization study used genetic proxies for GLP-1 receptor activation and found an association with reduced Alzheimer's disease risk that pointed toward direct cortical neuroprotection rather than indirect metabolic benefit.
• Mendelian randomization estimates genetic predisposition, not a drug trial, so this is directional evidence — not proof. But it adds to a growing pattern suggesting the brain is a real target of this drug class.